Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot International flag

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions

: ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin - TTL Representation

Raw ttl | Download


@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

 a fhir:_Group ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:id [ fhir:v "179786"] ; # 
  fhir:meta [
fhir:versionId [ fhir:v "3" ] ;
fhir:lastUpdated [ fhir:v "2023-12-04T20:30:40.963Z"^^xsd:dateTime ] ;
    ( fhir:profile [
fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-definition"^^xsd:anyURI ;
fhir:link <http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-definition>     ] )
  ] ; # 
  fhir:text [
fhir:status [ fhir:v "extensions" ] ;
fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: Group</b><a name=\"179786\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource Group &quot;179786&quot; Version &quot;3&quot; Updated &quot;2023-12-04 20:30:40+0000&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-exposure-definition.html\">ExposureDefinition</a></p></div><p><b>Artifact related artifact</b>: </p><p><b>Artifact Title</b>: ExposureDefinition: Therapeutic-dose anticoagulation with heparin</p><p><b>Artifact URL</b>: <a href=\"https://fevir.net/resources/Group/179786\">https://fevir.net/resources/Group/179786</a></p><p><b>Artifact Publisher</b>: Computable Publishing LLC</p><p><b>Artifact Copyright</b>: https://creativecommons.org/licenses/by-nc-sa/4.0/</p><p><b>Artifact Contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>CombinationMethod</b>: any-of</p><blockquote><p><b>modifierExtension[http://hl7.org/fhir/StructureDefinition/artifact-status]</b></p></blockquote><p><b>identifier</b>: FEvIR Object Identifier: 179786</p><p><b>type</b>: animal</p><p><b>membership</b>: definitional</p><p><b>name</b>: ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin</p><p><b>description</b>: Description: therapeutic-dose anticoagulation with heparin\nNote: Therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin was administered according to local protocols for the treatment of acute venous thromboembolism for up to 14 days or until recovery; the latter was defined as hospital discharge or a discontinuation of supplemental oxygen for at least 24 hours.</p><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: ATTACC investigational arm</p><blockquote><p><b>CharacteristicTiming</b></p><blockquote><p><b>url</b></p><code>contextCode</code></blockquote><p><b>value</b>: Start of trial <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><blockquote><p><b>url</b></p><code>offset</code></blockquote><p><b>value</b>: 0-14</p><blockquote><p><b>url</b></p><code>text</code></blockquote><p><b>value</b>: Up to 14 days or until hospital discharge or recovery (defined as liberation from supplemental oxygen&gt;24 hours, provided oxygen was required), whichever comes first.</p></blockquote><p><b>code</b>: Defined by CodeableConcept <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>value</b>: Therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from the need for supplemental oxygen, whichever comes first) with preference for low-molecular weight heparin (LMWH), or alternative unfractionated heparin (UFH). LMWH dosed according to patient weight and creatinine clearance according to local practice and policy. For UFH, suggested target of aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels. <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: ACTIV-4a investigational arm</p><blockquote><p><b>CharacteristicTiming</b></p><blockquote><p><b>url</b></p><code>contextCode</code></blockquote><p><b>value</b>: Start of trial <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><blockquote><p><b>url</b></p><code>offset</code></blockquote><p><b>value</b>: 0-14</p><blockquote><p><b>url</b></p><code>text</code></blockquote><p><b>value</b>: Up to 14 days or until hospital discharge, whichever comes first.</p></blockquote><p><b>code</b>: Defined by CodeableConcept <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>value</b>: Low-molecular weight heparin (LMWH) dosed according to patient weight and creatinine clearance. For UFH, suggested target of anti-Xa of 0.3-0.7 IU/ml or aPTT 1.5 to 2.5 times the upper limit of normal. <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: REMAP-CAP investigational arm</p><blockquote><p><b>CharacteristicTiming</b></p><blockquote><p><b>url</b></p><code>contextCode</code></blockquote><p><b>value</b>: Start of trial <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><blockquote><p><b>url</b></p><code>offset</code></blockquote><p><b>value</b>: 0-14</p><blockquote><p><b>url</b></p><code>text</code></blockquote><p><b>value</b>: Up to 14 days or until hospital discharge, whichever comes first.</p></blockquote><p><b>code</b>: Defined by CodeableConcept <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>value</b>: Dosed according to local hospital policy, practice, and guidelines for treatment of venous thromboembolism. Low-molecular weight heparin (LMWH) dosed according to patient weight. For UFH, suggested target for aPTT of 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels. <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>exclude</b>: false</p></blockquote></div>"
  ] ; # 
  fhir:extension ( [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact"^^xsd:anyURI ] ;
fhir:value [
a fhir:RelatedArtifact ;
fhir:type [ fhir:v "cite-as" ] ;
fhir:citation [ fhir:v "ExposureDefinition: Therapeutic-dose anticoagulation with heparin [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179786. Revised 2023-11-30. Available at: https://fevir.net/resources/Group/179786. Computable resource at: https://fevir.net/resources/Group/179786." ]     ]
  ] [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/artifact-title"^^xsd:anyURI ] ;
fhir:value [ fhir:v "ExposureDefinition: Therapeutic-dose anticoagulation with heparin" ]
  ] [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/artifact-url"^^xsd:anyURI ] ;
fhir:value [ fhir:v "https://fevir.net/resources/Group/179786"^^xsd:anyURI ]
  ] [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/artifact-publisher"^^xsd:anyURI ] ;
fhir:value [ fhir:v "Computable Publishing LLC" ]
  ] [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/artifact-copyright"^^xsd:anyURI ] ;
fhir:value [ fhir:v "https://creativecommons.org/licenses/by-nc-sa/4.0/" ]
  ] [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/artifact-contact"^^xsd:anyURI ] ;
fhir:value [
a fhir:ContactDetail ;
      ( fhir:telecom [
fhir:system [ fhir:v "email" ] ;
fhir:value [ fhir:v "support@computablepublishing.com" ]       ] )     ]
  ] [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/artifact-author"^^xsd:anyURI ] ;
fhir:value [
a fhir:ContactDetail ;
fhir:name [ fhir:v "Brian S. Alper" ]     ]
  ] [
fhir:url [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/combination-method"^^xsd:anyURI ] ;
fhir:value [ fhir:v "any-of" ]
  ] ) ; # 
  fhir:modifierExtension ( [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/artifact-status"^^xsd:anyURI ] ;
fhir:value [ fhir:v "active" ]
  ] ) ; # 
  fhir:identifier ( [
fhir:type [
      ( fhir:coding [
fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ] ;
fhir:code [ fhir:v "ACSN" ] ;
fhir:display [ fhir:v "Accession ID" ]       ] ) ;
fhir:text [ fhir:v "FEvIR Object Identifier" ]     ] ;
fhir:system [ fhir:v "https://fevir.net"^^xsd:anyURI ] ;
fhir:value [ fhir:v "179786" ] ;
fhir:assigner [
fhir:display [ fhir:v "Computable Publishing LLC" ]     ]
  ] ) ; # 
  fhir:type [ fhir:v "animal"] ; # 
  fhir:membership [ fhir:v "definitional"] ; # 
  fhir:name [ fhir:v "ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin"] ; # 
  fhir:description [ fhir:v "Description: therapeutic-dose anticoagulation with heparin\nNote: Therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin was administered according to local protocols for the treatment of acute venous thromboembolism for up to 14 days or until recovery; the latter was defined as hospital discharge or a discontinuation of supplemental oxygen for at least 24 hours."] ; # 
  fhir:characteristic ( [
    ( fhir:extension [
fhir:url [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description"^^xsd:anyURI ] ;
fhir:value [ fhir:v "ATTACC investigational arm" ]     ] [
      ( fhir:extension [
fhir:url [ fhir:v "contextCode"^^xsd:anyURI ] ;
fhir:value [
a fhir:CodeableConcept ;
fhir:text [ fhir:v "Start of trial" ]         ]       ] [
fhir:url [ fhir:v "offset"^^xsd:anyURI ] ;
fhir:value [
a fhir:Range ;
fhir:low [
fhir:value [ fhir:v "0"^^xsd:decimal ]           ] ;
fhir:high [
fhir:value [ fhir:v "14"^^xsd:decimal ] ;
fhir:unit [ fhir:v "days" ] ;
fhir:system [ fhir:v "http://unitsofmeasure.org"^^xsd:anyURI ] ;
fhir:code [ fhir:v "d" ]           ]         ]       ] [
fhir:url [ fhir:v "text"^^xsd:anyURI ] ;
fhir:value [ fhir:v "Up to 14 days or until hospital discharge or recovery (defined as liberation from supplemental oxygen>24 hours, provided oxygen was required), whichever comes first." ]       ] ) ;
fhir:url [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing"^^xsd:anyURI ]     ] ) ;
fhir:code [
fhir:text [ fhir:v "Defined by CodeableConcept" ]     ] ;
fhir:value [
a fhir:CodeableConcept ;
fhir:text [ fhir:v "Therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from the need for supplemental oxygen, whichever comes first) with preference for low-molecular weight heparin (LMWH), or alternative unfractionated heparin (UFH). LMWH dosed according to patient weight and creatinine clearance according to local practice and policy. For UFH, suggested target of aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels." ]     ] ;
fhir:exclude [ fhir:v "false"^^xsd:boolean ]
  ] [
    ( fhir:extension [
fhir:url [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description"^^xsd:anyURI ] ;
fhir:value [ fhir:v "ACTIV-4a investigational arm" ]     ] [
      ( fhir:extension [
fhir:url [ fhir:v "contextCode"^^xsd:anyURI ] ;
fhir:value [
a fhir:CodeableConcept ;
fhir:text [ fhir:v "Start of trial" ]         ]       ] [
fhir:url [ fhir:v "offset"^^xsd:anyURI ] ;
fhir:value [
a fhir:Range ;
fhir:low [
fhir:value [ fhir:v "0"^^xsd:decimal ]           ] ;
fhir:high [
fhir:value [ fhir:v "14"^^xsd:decimal ] ;
fhir:unit [ fhir:v "days" ] ;
fhir:system [ fhir:v "http://unitsofmeasure.org"^^xsd:anyURI ] ;
fhir:code [ fhir:v "d" ]           ]         ]       ] [
fhir:url [ fhir:v "text"^^xsd:anyURI ] ;
fhir:value [ fhir:v "Up to 14 days or until hospital discharge, whichever comes first." ]       ] ) ;
fhir:url [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing"^^xsd:anyURI ]     ] ) ;
fhir:code [
fhir:text [ fhir:v "Defined by CodeableConcept" ]     ] ;
fhir:value [
a fhir:CodeableConcept ;
fhir:text [ fhir:v "Low-molecular weight heparin (LMWH) dosed according to patient weight and creatinine clearance. For UFH, suggested target of anti-Xa of 0.3-0.7 IU/ml or aPTT 1.5 to 2.5 times the upper limit of normal." ]     ] ;
fhir:exclude [ fhir:v "false"^^xsd:boolean ]
  ] [
    ( fhir:extension [
fhir:url [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description"^^xsd:anyURI ] ;
fhir:value [ fhir:v "REMAP-CAP investigational arm" ]     ] [
      ( fhir:extension [
fhir:url [ fhir:v "contextCode"^^xsd:anyURI ] ;
fhir:value [
a fhir:CodeableConcept ;
fhir:text [ fhir:v "Start of trial" ]         ]       ] [
fhir:url [ fhir:v "offset"^^xsd:anyURI ] ;
fhir:value [
a fhir:Range ;
fhir:low [
fhir:value [ fhir:v "0"^^xsd:decimal ]           ] ;
fhir:high [
fhir:value [ fhir:v "14"^^xsd:decimal ] ;
fhir:unit [ fhir:v "days" ] ;
fhir:system [ fhir:v "http://unitsofmeasure.org"^^xsd:anyURI ] ;
fhir:code [ fhir:v "d" ]           ]         ]       ] [
fhir:url [ fhir:v "text"^^xsd:anyURI ] ;
fhir:value [ fhir:v "Up to 14 days or until hospital discharge, whichever comes first." ]       ] ) ;
fhir:url [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing"^^xsd:anyURI ]     ] ) ;
fhir:code [
fhir:text [ fhir:v "Defined by CodeableConcept" ]     ] ;
fhir:value [
a fhir:CodeableConcept ;
fhir:text [ fhir:v "Dosed according to local hospital policy, practice, and guidelines for treatment of venous thromboembolism. Low-molecular weight heparin (LMWH) dosed according to patient weight. For UFH, suggested target for aPTT of 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels." ]     ] ;
fhir:exclude [ fhir:v "false"^^xsd:boolean ]
  ] ) . #